Additional clinical data from the Phase II study with Ablynx’s anti-vWF-Nanobody┬«, caplacizumab, presented at the American Society of Hematology Annual Meeting, was discussed during a webcast on Thursday 11 December at 15h CET, 9 am EST.
Click here to replay the webcast